<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03374358</url>
  </required_header>
  <id_info>
    <org_study_id>OBERAL</org_study_id>
    <nct_id>NCT03374358</nct_id>
  </id_info>
  <brief_title>Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir</brief_title>
  <acronym>OBERAL</acronym>
  <official_title>Effect on Liver Fat, Adipose Tissue and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Once Daily Raltegravir in HIV+ Patients With Body Mass Index Over 25 kg/m2 and With at Least One Metabolic Syndrome Component</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide data on the switch from a protease inhibitor or efavirenz to the new&#xD;
      formulation of raltegravir (RAL) dosed once daily. The study group consists of patients with&#xD;
      metabolic risk factors and co-morbidities, in need of optimization of their current ART to&#xD;
      minimize the drug-related metabolic side effects as standard of care.&#xD;
&#xD;
      The primary objective of this study is to investigate whether switching a protease inhibitor&#xD;
      (PI) or efavirenz to raltegravir once daily reduces liver fat in patients who are overweight&#xD;
      or obese and have at least one metabolic syndrome component. For this purpose, the liver fat&#xD;
      content will be analyzed using the proton magnetic resonance spectroscopy.&#xD;
&#xD;
      In addition, the aim is to clarify the change in the body composition and metabolism in this&#xD;
      study group. For this purpose the visceral adipose tissue (VAT) and subcutaneous adipose&#xD;
      tissue (SAT) volumes will be measured and subcutaneous tissue samples will be collected for&#xD;
      future analyses of adipose tissue function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalences of overweight (body-mass-index, BMI 25-30 kg/m2) and obesity (BMI&gt;30 kg/m2)&#xD;
      are steadily increasing among HIV-infected patients globally. In parallel, the risk of&#xD;
      non-alcoholic fatty liver disease (NAFLD) increases. Clinically alarming are the data which&#xD;
      suggest that HIV infected have higher rates of progressive form of NAFLD than non-HIV&#xD;
      infected age, gender and BMI matched controls.&#xD;
&#xD;
      As the treatment for HIV is life-long, it is crucial to understand the effects of different&#xD;
      antiretroviral therapy (ART) regimens on metabolism. Some antiretroviral agents appear to&#xD;
      promote unfavourable changes in metabolism (e.g. in blood lipids) and predispose to trunk fat&#xD;
      redistribution and liver fat accumulation.&#xD;
&#xD;
      Raltegravir has been demonstrated to have beneficial impact on some metabolic parameters&#xD;
      compared to the protease inhibitor class or efavirenz. In this study, the aim is to&#xD;
      investigate whether switching a protease inhibitor or efavirenz to raltegravir reduces liver&#xD;
      fat in patients who are overweight or obese and have at least one metabolic syndrome&#xD;
      component. For this purpose, the proton magnetic resonance spectroscopy will be used.&#xD;
&#xD;
      In addition, the aim is to clarify the change in the body composition in this study group.&#xD;
      For this purpose, the visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT)&#xD;
      volumes will be measured using MRI.&#xD;
&#xD;
      To acquire more knowledge on metabolic effects in adipose tissue level, subcutaneous adipose&#xD;
      tissue biopsies will be collected together with blood, saliva and feces samples.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2018</start_date>
  <completion_date type="Actual">November 30, 2019</completion_date>
  <primary_completion_date type="Actual">November 2, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study is a randomized, open, parallel design study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Liver Fat</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>24 week value minus baseline value, liver fat % measured by proton magnetic resonance spectroscopy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Subcutaneous and Visceral Adipose Tissue Volume</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>24 week value minus baseline value: change in subcutaneous (SAT) and visceral (VAT) adipose tissue volume (mL) measured by magnetic resonance imaging. Analysis included a series of T1-weighted trans-axial images from 8 cm above to 8 cm below the 4th and 5th lumbar intervertebral disc (16 slices, field of view 375 x 500 mm2, slice thickness 10 mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight and Total Body Fat</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>24 week value minus baseline value, change in body weight (kg) and total body fat (kg) measured by Bioelectrical Impedance Analysis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Liver Stiffness</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>24 week minus baseline value, change in liver stiffness (kPa) measured by transient elastography (Fibroscan Â®).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Fasting Plasma Glucose</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>24 week value minus baseline value, change in fasting plasma glucose (mg/dL).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Fasting Serum Lipid Profile</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>24 week value minus baseline value, change in fasting serum lipid profile: LDL and HDL cholesterol, triglyceride (all values in mmol/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Metabolic and Inflammatory Biomarkers: hsCRP</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>24 week value minus baseline value, change in circulating metabolic and inflammatory biomarkers: high sensitivity C-reactive protein (hsCRP mg/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Metabolic and Inflammatory Biomarkers: IL-6</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>24 week value minus baseline value, change in circulating metabolic and inflammatory biomarkers: interleukin 6 (IL-6 pg/mL)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>HIV Seropositivity</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Fatty Liver</condition>
  <arm_group>
    <arm_group_label>No intervention arm.</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Study subjects will continue their current antiretroviral regimens, which include a protease inhibitor or efavirenz plus two nucleoside analog reverse-transcriptase inhibitors (NRTIs).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Raltegravir arm.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects will switch their protease inhibitor or efavirenz to once daily raltegravir plus continue current nucleoside analog reverse-transcriptase inhibitors (NRTIs).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .</description>
    <arm_group_label>Raltegravir arm.</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent (IC) obtained.&#xD;
&#xD;
          -  HIV-positive adult (age over 18) subjects currently on stable ART, with no changes in&#xD;
             the ART regimens during the past 6 months.&#xD;
&#xD;
          -  Current ART includes either a protease inhibitor or efavirenz.&#xD;
&#xD;
          -  No documented or suspected resistance to integrase inhibitors or to NRTIs.&#xD;
&#xD;
          -  No prior history of virologic failure. Failure is defined as a confirmed plasma viral&#xD;
             load &gt; 200 cop/ml measured no less than six months after initiation or modification of&#xD;
             therapy.&#xD;
&#xD;
          -  Virological blips accepted only if a single viral load measurement has been between&#xD;
             50-200 cop/ml followed by viral load &lt; 50 cop/ml without the need to initiate a change&#xD;
             in ART and no blip within 12 month window period prior to screening.&#xD;
&#xD;
          -  Documented evidence of at least two HIV viral load &lt; 50 cop/ml measurements during the&#xD;
             past 12 months prior to inclusion: one within 6 months prior to screening.&#xD;
&#xD;
          -  HIV viral load &lt; 50 cop/ml at screening.&#xD;
&#xD;
          -  BMI&gt;25 kg/m2 and one metabolic syndrome condition, which are&#xD;
&#xD;
               -  BP â¥ 130/â¥ 85 mmHg or hypertension medication currently in use or&#xD;
&#xD;
               -  fasting glucose â¥ 5.6 mmol/l or B-HbA1C &gt; 42 mmol/mol or diabetes medication&#xD;
                  currently in use or&#xD;
&#xD;
               -  HDL &lt; 1.0 mmol/l in men and &lt; 1.3 mmol/l in women or triglycerides â¥ 1.7 mmol/l&#xD;
                  or a cholesterol-lowering regimen currently in use or&#xD;
&#xD;
               -  waist circumference &gt; 94 cm in men and &gt;80 cm in women (or respective cut off&#xD;
                  values for non-European ethnic groups as defined by International Diabetes&#xD;
                  Federation). OR&#xD;
&#xD;
          -  ultrasound or biopsy proven hepatosteatosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Within 12 month window period prior to screening, HIV viral load measurement of &gt;50&#xD;
             cop/ml.&#xD;
&#xD;
          -  More than one consecutive HIV viral load measurements of &gt; 50 cop/ml in the treatment&#xD;
             history after initial viral suppression with ART.&#xD;
&#xD;
          -  Chronic hepatitis B or C.&#xD;
&#xD;
          -  Daily alcohol consumption â¥ 30 g for men and â¥ 20 g for women.&#xD;
&#xD;
          -  Pregnancy or planned pregnancy during the study period.&#xD;
&#xD;
          -  Lipid or glucose lowering regimen or hormonal supplement started within 3 months&#xD;
             before the planned study start.&#xD;
&#xD;
          -  Psychiatric disorder, which prevents a study subject to understand the study protocol.&#xD;
&#xD;
          -  Other serious disease, which prevents a study subject to participate in the study.&#xD;
&#xD;
          -  For MRI/spectroscopy imaging: metal objects in the body or claustrophobia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jussi Sutinen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aurora hospital, Department of Infectious Diseases</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 2, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2017</study_first_posted>
  <results_first_submitted>May 19, 2021</results_first_submitted>
  <results_first_submitted_qc>June 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 7, 2021</results_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Jussi Sutinen</investigator_full_name>
    <investigator_title>Consultant, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Seropositivity</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT03374358/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Control (= no Intervention Arm).</title>
          <description>Study subjects will continue their current antiretroviral regimens, which include a protease inhibitor or efavirenz plus two nucleoside analog reverse-transcriptase inhibitors (NRTIs).</description>
        </group>
        <group group_id="P2">
          <title>Raltegravir Arm.</title>
          <description>Study subjects will switch their protease inhibitor or efavirenz to once daily raltegravir plus continue current nucleoside analog reverse-transcriptase inhibitors (NRTIs).&#xD;
Raltegravir: The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Control (= no Intervention Arm).</title>
          <description>Study subjects will continue their current antiretroviral regimens, which include a protease inhibitor or efavirenz plus two nucleoside analog reverse-transcriptase inhibitors (NRTIs).</description>
        </group>
        <group group_id="B2">
          <title>Raltegravir Arm.</title>
          <description>Study subjects will switch their protease inhibitor or efavirenz to once daily raltegravir plus continue current nucleoside analog reverse-transcriptase inhibitors (NRTIs).&#xD;
Raltegravir: The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="43" upper_limit="62"/>
                    <measurement group_id="B2" value="49" lower_limit="39" upper_limit="54"/>
                    <measurement group_id="B3" value="49" lower_limit="42" upper_limit="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Finland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="24"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liver fat content</title>
          <description>%, measured by proton magnetic resonance spectroscopy</description>
          <population>Only those participants with data available at the specified time points were analyzed.</population>
          <units>% hepatic fat fraction</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.1" lower_limit="1.6" upper_limit="7.3"/>
                    <measurement group_id="B2" value="2.3" lower_limit="1.1" upper_limit="6.0"/>
                    <measurement group_id="B3" value="2.3" lower_limit="1.4" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Subcutaneous adipose tissue volume</title>
          <population>Only those participants with data available at the specified time points were analyzed.</population>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5377" lower_limit="3693" upper_limit="8237"/>
                    <measurement group_id="B2" value="3979" lower_limit="2068" upper_limit="6468"/>
                    <measurement group_id="B3" value="4468" lower_limit="2547" upper_limit="6146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visceral adipose tissue volume</title>
          <population>Only those participants with data available at the specified time points were analyzed.</population>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="18"/>
                    <count group_id="B3" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2053" lower_limit="1906" upper_limit="2886"/>
                    <measurement group_id="B2" value="1795" lower_limit="1249" upper_limit="3164"/>
                    <measurement group_id="B3" value="1906" lower_limit="1539" upper_limit="2349"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <population>Only those participants with data available at the specified time points were analyzed.</population>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98.8" lower_limit="89.2" upper_limit="106.7"/>
                    <measurement group_id="B2" value="85.9" lower_limit="76.1" upper_limit="97.7"/>
                    <measurement group_id="B3" value="93.2" lower_limit="80.4" upper_limit="101.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total body fat</title>
          <description>Measured by bioelectrical impedance analysis.</description>
          <population>Only those participants with data available at the specified data points were analyzed.</population>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.0" lower_limit="23.6" upper_limit="48.6"/>
                    <measurement group_id="B2" value="20.3" lower_limit="14.6" upper_limit="29.7"/>
                    <measurement group_id="B3" value="23.8" lower_limit="17.3" upper_limit="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liver stiffness</title>
          <description>Measured by transient elastography (Fibroscsan).</description>
          <population>Only those participants with data available at the specified time points were analyzed.</population>
          <units>kPa</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.7" lower_limit="4.1" upper_limit="5.5"/>
                    <measurement group_id="B2" value="4.1" lower_limit="3.3" upper_limit="5.6"/>
                    <measurement group_id="B3" value="4.4" lower_limit="3.6" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting plasma glucose</title>
          <population>Only those participants with data available at the specified time points were analyzed.</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.0" lower_limit="5.7" upper_limit="6.3"/>
                    <measurement group_id="B2" value="5.5" lower_limit="5.3" upper_limit="6.0"/>
                    <measurement group_id="B3" value="5.7" lower_limit="5.5" upper_limit="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting serum LDL cholesterol</title>
          <population>Only those participants with data available at the specific data points were analyzed.</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.2" lower_limit="2.8" upper_limit="3.5"/>
                    <measurement group_id="B2" value="3.2" lower_limit="2.7" upper_limit="3.6"/>
                    <measurement group_id="B3" value="3.2" lower_limit="2.7" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting serum HDL cholesterol</title>
          <population>Only those participants with data available at the specified data points were analyzed.</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.13" lower_limit="0.98" upper_limit="1.28"/>
                    <measurement group_id="B2" value="1.30" lower_limit="1.02" upper_limit="1.39"/>
                    <measurement group_id="B3" value="1.20" lower_limit="1.01" upper_limit="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting serum triglyceride</title>
          <population>Only those participants with data available at the specified data points were analyzed.</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3" lower_limit="1.1" upper_limit="1.8"/>
                    <measurement group_id="B2" value="1.3" lower_limit="1.1" upper_limit="2.2"/>
                    <measurement group_id="B3" value="1.3" lower_limit="1.1" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum high sensitivity CRP</title>
          <population>Only those participants with data available at the specified data points were analyzed.</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="42"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.4" lower_limit="1.0" upper_limit="3.7"/>
                    <measurement group_id="B2" value="1.0" lower_limit="0.6" upper_limit="2.4"/>
                    <measurement group_id="B3" value="1.3" lower_limit="0.7" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum IL-6</title>
          <population>Only those participants with data available at the specified data points were analyzed.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="22"/>
                    <count group_id="B2" value="19"/>
                    <count group_id="B3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.2" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="B2" value="2.4" lower_limit="1.5" upper_limit="3.3"/>
                    <measurement group_id="B3" value="2.2" lower_limit="1.7" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Liver Fat</title>
        <description>24 week value minus baseline value, liver fat % measured by proton magnetic resonance spectroscopy.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control (= no Intervention Arm).</title>
            <description>Study subjects will continue their current antiretroviral regimens, which include a protease inhibitor or efavirenz plus two nucleoside analog reverse-transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir Arm.</title>
            <description>Study subjects will switch their protease inhibitor or efavirenz to once daily raltegravir plus continue current nucleoside analog reverse-transcriptase inhibitors (NRTIs).&#xD;
Raltegravir: The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Liver Fat</title>
          <description>24 week value minus baseline value, liver fat % measured by proton magnetic resonance spectroscopy.</description>
          <population>Only those participants with data available at the specified time points were analyzed.</population>
          <units>% hepatic fat fraction</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" lower_limit="-0.5" upper_limit="2.7"/>
                    <measurement group_id="O2" value="0.6" lower_limit="-0.3" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Subcutaneous and Visceral Adipose Tissue Volume</title>
        <description>24 week value minus baseline value: change in subcutaneous (SAT) and visceral (VAT) adipose tissue volume (mL) measured by magnetic resonance imaging. Analysis included a series of T1-weighted trans-axial images from 8 cm above to 8 cm below the 4th and 5th lumbar intervertebral disc (16 slices, field of view 375 x 500 mm2, slice thickness 10 mm).</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control (= no Intervention Arm).</title>
            <description>Study subjects will continue their current antiretroviral regimens, which include a protease inhibitor or efavirenz plus two nucleoside analog reverse-transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir Arm.</title>
            <description>Study subjects will switch their protease inhibitor or efavirenz to once daily raltegravir plus continue current nucleoside analog reverse-transcriptase inhibitors (NRTIs).&#xD;
Raltegravir: The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Subcutaneous and Visceral Adipose Tissue Volume</title>
          <description>24 week value minus baseline value: change in subcutaneous (SAT) and visceral (VAT) adipose tissue volume (mL) measured by magnetic resonance imaging. Analysis included a series of T1-weighted trans-axial images from 8 cm above to 8 cm below the 4th and 5th lumbar intervertebral disc (16 slices, field of view 375 x 500 mm2, slice thickness 10 mm).</description>
          <population>Only those participants with data available at the specified time points were analyzed.</population>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in SAT (24 weeks - baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-74" lower_limit="-627" upper_limit="202"/>
                    <measurement group_id="O2" value="242" lower_limit="27" upper_limit="341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in VAT (24 weeks - baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="-126" upper_limit="569"/>
                    <measurement group_id="O2" value="66" lower_limit="-149" upper_limit="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight and Total Body Fat</title>
        <description>24 week value minus baseline value, change in body weight (kg) and total body fat (kg) measured by Bioelectrical Impedance Analysis.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Only those participants with data available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control (= no Intervention Arm).</title>
            <description>Study subjects will continue their current antiretroviral regimens, which include a protease inhibitor or efavirenz plus two nucleoside analog reverse-transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir Arm.</title>
            <description>Study subjects will switch their protease inhibitor or efavirenz to once daily raltegravir plus continue current nucleoside analog reverse-transcriptase inhibitors (NRTIs).&#xD;
Raltegravir: The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight and Total Body Fat</title>
          <description>24 week value minus baseline value, change in body weight (kg) and total body fat (kg) measured by Bioelectrical Impedance Analysis.</description>
          <population>Only those participants with data available at the specified time points were analyzed.</population>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in body weight (24 weeks - baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="-1.8" upper_limit="4.1"/>
                    <measurement group_id="O2" value="2.0" lower_limit="0.4" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in body fat (24 weeks - baseline)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" lower_limit="-1.7" upper_limit="1.5"/>
                    <measurement group_id="O2" value="1.5" lower_limit="0.1" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Liver Stiffness</title>
        <description>24 week minus baseline value, change in liver stiffness (kPa) measured by transient elastography (Fibroscan Â®).</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control (= no Intervention Arm).</title>
            <description>Study subjects will continue their current antiretroviral regimens, which include a protease inhibitor or efavirenz plus two nucleoside analog reverse-transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir Arm.</title>
            <description>Study subjects will switch their protease inhibitor or efavirenz to once daily raltegravir plus continue current nucleoside analog reverse-transcriptase inhibitors (NRTIs).&#xD;
Raltegravir: The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Liver Stiffness</title>
          <description>24 week minus baseline value, change in liver stiffness (kPa) measured by transient elastography (Fibroscan Â®).</description>
          <population>Only those participants with data available at the specified data points were analyzed.</population>
          <units>kPa</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-1.2" upper_limit="0.6"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-1.6" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Fasting Plasma Glucose</title>
        <description>24 week value minus baseline value, change in fasting plasma glucose (mg/dL).</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control (= no Intervention Arm).</title>
            <description>Study subjects will continue their current antiretroviral regimens, which include a protease inhibitor or efavirenz plus two nucleoside analog reverse-transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir Arm.</title>
            <description>Study subjects will switch their protease inhibitor or efavirenz to once daily raltegravir plus continue current nucleoside analog reverse-transcriptase inhibitors (NRTIs).&#xD;
Raltegravir: The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Plasma Glucose</title>
          <description>24 week value minus baseline value, change in fasting plasma glucose (mg/dL).</description>
          <population>Only those participants with data available at the specified data points were analyzed.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-7.2" upper_limit="5.4"/>
                    <measurement group_id="O2" value="-1.8" lower_limit="-10.8" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Fasting Serum Lipid Profile</title>
        <description>24 week value minus baseline value, change in fasting serum lipid profile: LDL and HDL cholesterol, triglyceride (all values in mmol/L)</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control (= no Intervention Arm).</title>
            <description>Study subjects will continue their current antiretroviral regimens, which include a protease inhibitor or efavirenz plus two nucleoside analog reverse-transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir Arm.</title>
            <description>Study subjects will switch their protease inhibitor or efavirenz to once daily raltegravir plus continue current nucleoside analog reverse-transcriptase inhibitors (NRTIs).&#xD;
Raltegravir: The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Serum Lipid Profile</title>
          <description>24 week value minus baseline value, change in fasting serum lipid profile: LDL and HDL cholesterol, triglyceride (all values in mmol/L)</description>
          <population>Only those participants with data available at the specified data points were analyzed.</population>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in fasting serum LDL (24 weeks - baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-0.4" upper_limit="0.4"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-1.0" upper_limit="-0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in fasting serum HDL (24 weeks - baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="-0.07" upper_limit="0.15"/>
                    <measurement group_id="O2" value="-0.07" lower_limit="-0.16" upper_limit="-0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in fasting serum triglycerides (24 weeks - baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" lower_limit="-0.28" upper_limit="0.20"/>
                    <measurement group_id="O2" value="-0.18" lower_limit="-0.49" upper_limit="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Metabolic and Inflammatory Biomarkers: hsCRP</title>
        <description>24 week value minus baseline value, change in circulating metabolic and inflammatory biomarkers: high sensitivity C-reactive protein (hsCRP mg/L)</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control (= no Intervention Arm).</title>
            <description>Study subjects will continue their current antiretroviral regimens, which include a protease inhibitor or efavirenz plus two nucleoside analog reverse-transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir Arm.</title>
            <description>Study subjects will switch their protease inhibitor or efavirenz to once daily raltegravir plus continue current nucleoside analog reverse-transcriptase inhibitors (NRTIs).&#xD;
Raltegravir: The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Metabolic and Inflammatory Biomarkers: hsCRP</title>
          <description>24 week value minus baseline value, change in circulating metabolic and inflammatory biomarkers: high sensitivity C-reactive protein (hsCRP mg/L)</description>
          <population>Only those participants with data available at the specified data points were analyzed.</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" lower_limit="-0.07" upper_limit="1.45"/>
                    <measurement group_id="O2" value="-0.06" lower_limit="-0.59" upper_limit="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Metabolic and Inflammatory Biomarkers: IL-6</title>
        <description>24 week value minus baseline value, change in circulating metabolic and inflammatory biomarkers: interleukin 6 (IL-6 pg/mL)</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <population>Only those participants with data available at the specified data points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Control (= no Intervention Arm).</title>
            <description>Study subjects will continue their current antiretroviral regimens, which include a protease inhibitor or efavirenz plus two nucleoside analog reverse-transcriptase inhibitors (NRTIs).</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir Arm.</title>
            <description>Study subjects will switch their protease inhibitor or efavirenz to once daily raltegravir plus continue current nucleoside analog reverse-transcriptase inhibitors (NRTIs).&#xD;
Raltegravir: The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Metabolic and Inflammatory Biomarkers: IL-6</title>
          <description>24 week value minus baseline value, change in circulating metabolic and inflammatory biomarkers: interleukin 6 (IL-6 pg/mL)</description>
          <population>Only those participants with data available at the specified data points were analyzed.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" lower_limit="-0.09" upper_limit="1.20"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.87" upper_limit="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Control (= no Intervention Arm).</title>
          <description>Study subjects will continue their current antiretroviral regimens, which include a protease inhibitor or efavirenz plus two nucleoside analog reverse-transcriptase inhibitors (NRTIs).</description>
        </group>
        <group group_id="E2">
          <title>Raltegravir Arm.</title>
          <description>Study subjects will switch their protease inhibitor or efavirenz to once daily raltegravir plus continue current nucleoside analog reverse-transcriptase inhibitors (NRTIs).&#xD;
Raltegravir: The aim of this study is to investigate whether switching a protease inhibitor (PI) or efavirenz to raltegravir has effect on liver fat and metabolism in HIV-infected patients who are overweight or obese and have at least one metabolic syndrome component .</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal (diarrhoea, nausea)</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dizzyness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleeping difficulties</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Jussi Sutinen</name_or_title>
      <organization>Helsinki University Hospital</organization>
      <phone>+358407480437</phone>
      <email>jussi.sutinen@hus.fi</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

